Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus
Author: Vincent, F.B.
Kandane-Rathnayake, R.
Hoi, A.Y.
Slavin, L.
Godsell, J.D.
Kitching, A.R.
Harris, J.
Nelson, C.L.
Jenkins, A.J.
Chrysostomou, A.
Hibbs, M.L.
Kerr, P.G.
Rischmueller, M.
Mackay, F.
Morand, E.F.
Citation: Lupus, 2018; 27(13):2029-2040
Publisher: SAGE Publishing
Issue Date: 2018
ISSN: 0961-2033
Statement of
F B Vincent, R Kandane-Rathnayake, A Y Hoi, L Slavin, J D Godsell, A R Kitching, J Harris, C L Nelson, A J Jenkins, A Chrysostomou, M L Hibbs, P G Kerr, M Rischmueller, F Mackay, E F Morand
Abstract: INTRODUCTION:We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE). METHODS:We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000. RESULTS:uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease. CONCLUSIONS:uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.
Keywords: A proliferation-inducing ligand (APRIL); B-cell–activating factor from the tumour necrosis factor family (BAFF); biomarker; lupus nephritis (LN); monocyte chemoattractant protein 1 (MCP-1); systemic lupus erythematosus (SLE)
Rights: © The Author(s), 2018. Reprints and permissions:
DOI: 10.1177/0961203318804885
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.